Novo Nordisk's Next-Gen Diabetes Candidate Could Challenge Ozempic -- Is the Stock a Buy?

The company should maintain its lead in this growing area.Novo Nordisk (NVO -0.88%) is under attack. Although the Denmark-based drugmaker is a pioneer and leader in the GLP-1 diabetes and weight loss drug markets, countless companies are trying to steal its lunch. It's no wonder: Ozempic, a diabetes medicine, and Wegovy, a weight loss therapy with the same active ingredient, have both seen incredible success. Challengers were bound to rise, eventually. However, Novo Nordisk is also working on potential succ ...